FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Federal Register

Canadian Drug Importation: Information Collection

Federal Register notice: FDA sends to OMB an information collection extension entitled Importation of Prescription Drugs from Canada.

latest-news-card-1
Medical Devices

InfoBionic Next-Gen Cardiac Monitor

FDA clears an InfoBionic 510(k) for its MoMe ARC, the companys third-generation remote electrocardiogram monitoring device.

Medical Devices

Heidelberg Engineering Ocular Platform Cleared

FDA clears a Heidelberg Engineering 510(k) for its ANTERION platform, which the company says is designed to transform anterior segment diagnostics and...

latest-news-card-1
Marketing

FDA to Study Adherence Effect on Promotion

The CDER Office of Prescription Drug Promotion says it plans to research adherence potential and patient preference in prescription drug promotion.

latest-news-card-1
Human Drugs

Topical Ophthalmic Drug Quality Guidance

FDA publishes a draft guidance on quality considerations for ophthalmic drug products indicated for topical delivery in and around the eye.

latest-news-card-1
Biologics

Stelara Biosimilar Gets Complete Response

Citing inspection findings that need to be resolved, FDA sends Alvotech a complete response letter for its BLA for AVT04, a biosimilar of Janssens Ste...

latest-news-card-1
Federal Register

Mekinist Not Withdrawn Due to Safety/Efficacy

Federal Register notice: FDA determines that Novartis Pharmaceuticals Mekinist (trametinib dimethyl sulfoxide) tablets (1 mg) were not withdrawn for s...

latest-news-card-1
Federal Register

Info Collection on Regulatory Misconduct Allegations

Federal Register notice: FDA sends to OMB an information collection extension entitled Allegations of Regulatory Misconduct Voluntarily Submitted to t...

latest-news-card-1
Human Drugs

3 Stakeholder Comments on FDA QTc Guidance

PhRMA suggests that FDA revise a draft guidance on QTc labeling to incorporate an International Council on Harmonization guideline.

latest-news-card-1
Biologics

Lilly Plans 2024 BLA for Crohns Drug

Reporting positive data from a Phase 3 study on mirikizumab in Crohns disease, Eli Lilly says it will seek FDA approval for the drug next year.